Reneo Pharmaceuticals And 2 Other Stocks Under $5 Executives Are Buying
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 17 2024
0mins
Source: Benzinga
Market Overview: The Dow Jones index rose over 200 points, with insider trading activity in penny stocks indicating investor confidence or concerns about company prospects.
Notable Insider Transactions: Recent purchases by insiders include Exicure acquiring shares for $711,669, Amylyx Pharmaceuticals' CFO buying shares for $101,368, and Reneo Pharmaceuticals' owner spending $484,344 on shares, all reflecting ongoing developments in their respective biotech fields.
Analyst Views on XCUR
About XCUR
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
